Piper Sandler Reiterates Overweight on Arrowhead Pharma, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $62.
October 08, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's analyst Edward Tenthoff has reiterated an Overweight rating on Arrowhead Pharma, maintaining a price target of $62. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $62 price target by Piper Sandler indicates a positive outlook on Arrowhead Pharma's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100